Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Chiauranib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Chipscreen Biosciences
- 21 Nov 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
- 18 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
- 29 May 2017 New trial record